Literature DB >> 9673798

Evidence that cannabinoid-induced inhibition of electrically evoked contractions of the myenteric plexus--longitudinal muscle preparation of guinea-pig small intestine can be modulated by Ca2+ and cAMP.

A A Coutts1, R G Pertwee.   

Abstract

Cannabinoid receptor agonists inhibit electrically evoked isometric contractions of the myenteric plexus--longitudinal muscle preparation of the guinea-pig small intestine (MPLM), probably by reducing release of acetylcholine (ACh) through the activation of prejunctional CB1 receptors. As CB1 receptors are thought to be negatively coupled through Gi/o proteins to both N-type Ca2+ channels and adenylate cyclase, we have now further investigated the involvement of CB1 receptors by monitoring the effects of forskolin, 8-bromo-cAMP, 3-isobutyl-1-methylxanthine (IBMX), and extracellular Ca2+ on the ability of the cannabinoid agonist, (+)-WIN 55212 to inhibit electrically evoked contractions of the MPLM (0.1 Hz, 0.5 ms, and 110% maximal voltage). Some experiments were performed with normorphine instead of (+)-WIN 55212. At 10(-7) M, forskolin, 8-bromo-cAMP, and IBMX were found to reduce significantly the maximum inhibitory response to (+)-WIN 55212 by 49.4, 48.4, and 40.2%, respectively, without affecting control contractions or responses to exogenous ACh. Low external Ca2+ (0.64 mM) significantly increased the maximum response to (+)-WIN 55212 and shifted the curve slightly leftwards, whereas high external Ca2+ (5.08 mM) reduced the maximum response by 27.2%. The concentration-response curve to normorphine, which also reduces evoked contractions of this preparation as a result of a presynaptic inhibition of ACh release via opioid mu receptors, was affected similarly. These results support the hypothesis that cannabinoid-induced inhibition in the MPLM is mediated by CB1 receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9673798

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  8 in total

1.  Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens.

Authors:  D Robbe; G Alonso; F Duchamp; J Bockaert; O J Manzoni
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

Review 2.  Cannabinoids and the gastrointestinal tract.

Authors:  R G Pertwee
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

3.  Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice.

Authors:  Angelo A Izzo; Raffaele Capasso; Gabriella Aviello; Francesca Borrelli; Barbara Romano; Fabiana Piscitelli; Laura Gallo; Francesco Capasso; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 4.  The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract.

Authors:  Federico Massa; Martin Storr; Beat Lutz
Journal:  J Mol Med (Berl)       Date:  2005-08-26       Impact factor: 4.599

5.  Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon.

Authors:  Nicholas M Hinds; Katja Ullrich; Scott D Smid
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

6.  Cannabis for the treatment of Crohn's disease.

Authors:  Tahir S Kafil; Tran M Nguyen; John K MacDonald; Nilesh Chande
Journal:  Cochrane Database Syst Rev       Date:  2018-11-08

7.  The dual effect of cannabinoid receptor-1 deficiency on the murine postoperative ileus.

Authors:  Yong-yu Li; Ming-hua Cao; Brigitte Goetz; Chun-qiu Chen; Ya-jing Feng; Chang-Jie Chen; Michael S Kasparek; Andrej Sibaev; Martin Storr; Martin E Kreis
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

Review 8.  The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease.

Authors:  C Hasenoehrl; U Taschler; M Storr; R Schicho
Journal:  Neurogastroenterol Motil       Date:  2016-08-26       Impact factor: 3.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.